Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in uganda

HIV/AIDS - Research and Palliative Care

Volumn 4, Issue , 2012, Pages 135-140

  Bray, Sarah ^a   Gedeon, Jillian ^a   Hadi, Ahsan ^a   Kotb, Ahmed ^a   Rahman, Tarun ^a   Sarwar, Elaha ^a   Savelyeva, Anna ^a   Sévigny, Marika ^a   Bakanda, Celestin ^b   Birungi, Josephine ^b   Chan, Keith ^c   Yaya, Sanni ^a   Deonandan, Raywat ^a   Mills, Edward J ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b THE AIDS SUPPORT ORGANIZATION   (Uganda)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral therapy; ART; CD4; Prognosis; Sub saharan africa

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PREDICTIVE VALUE; SEX DIFFERENCE; SURVIVAL TIME; TREATMENT DURATION; UGANDA;

EID: 84872979524     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S35374     Document Type: Article

References (34)

1. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568-2577.
2. Sterne JA, May M, Costagliola D, et al; For When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1- infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-1363.
3. Kitahata MM, Gange SJ, Abraham AG, et al; for NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Eng J Med. 2009;360(18):1815-1826.
4. World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children; 2007. Available from: http://www.who.int/hiv/pub/vct/hivstaging/en/index.html. Accessed June 10, 2012.
5. Thompson MA, Aberg JA, Cahn P, et al; For International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321-333.
6. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. Available at http://www.who.int/hiv/pub/arv/adult2010/en/. 2010. Accessed June 14, 2012.
7. Keiser O, Tweya H, Braitstein P, et al; For ART-LINC of IeDEA Study Group. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(2):251-258.
8. Mills E, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209-216.
9. Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR; For CASCADE Collaboration. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. Aids. 2011;25(11):1395-1403.
10. Chêne G, Sterne JA, May M, et al; For Antiretroviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362(9385):679-686.
11. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130(7): 570-577.
12. Mills EJ, Bakanda C, Birungi J, Yaya S, Ford N; For the TASO-CAN Writing Group. The prognostic value of baseline CD4 cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource- limited setting. Aids. 2012;26(11):1425-1429.
13. Ministry of Health. National Antiretroviral Treatment and Care Guidelines for Adults and Children. Kampala, Uganda: Earnest Publishers; 2010.
14. Mills EJ, Bakanda C, Birungi J, Yaya S, Ford N. The prognostic value of baseline CD4 cell count beyond 6 months of antiretroviral therapy in a resource-limited setting. Aids. 2012;26(11):1425-1429.
15. Kiboneka A, Nyatia R, Nabiryo C, et al. Combination antiretroviral therapy in population affected by confict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201.
16. Bakanda C, Birungi J, Nkoyooyo A, et al. Cohort Profile: The TASO- CAN Cohort Collaboration. Int J Epidemiol. March 7, 2011. [Epub ahead of print.]
17. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300(5):506-507.
18. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
19. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute Inc; 1995.
20. Yuan YC. Multiple Imputation for Missing Data: Concepts and New Development (Version 9.0). Available from http://analysis3. com/Multiple-Imputation-for-Missing-Data-Concepts-and-New- Development-pdf-e4976.pdf. Accessed July 15, 2012.
21. Rosen S, Fox M P, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Sarahan Africa: a systematic review. PLoS Med. 2007;4(10):e298.
22. Brinkhof M W, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource- limited settings: systematic review and meta-analysis. PLoS One. 2009;4(46):e5790.
23. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300(5):506-507.
24. Egger M, Spycher B, Sidle J, et al. Correcting mortality for loss to follow up: a graphical approach applied to art programmes in resource-limited settings. 5th IAS Conference on HIV Pathogenesis, Treatment and prevention, July 19-22, 2009, Cape Town, South Africa. Poster #WEPED173.
25. Braitstein P, Brinkhof M W, Dabis F, et al; For Antiretroviral Therapy in Lower Income Countries (ART-LINC Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817-824.
26. Ford N, Darder M, Spelman T, Maclean E, Mills E, Boulle A. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: fve-year follow up of an observational cohort. PLoS One. 2010;5(5):e10460.
27. Chang LW, Kagaayi J, Nakigozi G, et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One. 2010;5(6):e10923.
28. Braitstein P, Boulle A, Nash D, et al; for Antiretroviral Therapy in Lower Income Countries (ART-LINC) study group. Gender and the use of antiretroviral treatment in resource-constrained settings: fnd- ings from a multcenter collaboration. J Womens Health (Larchmt). 2008;17(1):47-55.
29. Muula AS, Ngulube TJ, Siziya S, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007;7:63.
30. Mills EJ, Ford N, Mugyenyi P. Expanding HIV care in Africa: making men matter. Lancet. 2009;374(9686):275-276.
31. Wachira J, Kimaiyo S, Ndege S, Mamlin J, Braitstein P. What is the impact of home-based HIV counseling and testing on the clinical status of newly enrolled adults in a large HIV care program in Western Kenya? Clin Infect Dis. 2012;54(2):275-281.
32. Braitstein P, Boulle A, Nash D, et al; For Antiretroviral Therapy in Lower Income Countries (ART-LINC) study group. Gender and the use of antiretroviral treatment in resource-constrained settings: fnd- ings from a multicenter collaboration. J Womens Health (Larchmt). 2008;17(1):47-55.
33. Cohen MS, Chen YQ, McCauley M, et al; For HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
34. Larson BA, Fox M P, Rosen S, et al. Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health. 2009;9:240.